期刊
JOURNAL OF THORACIC ONCOLOGY
卷 4, 期 11, 页码 1389-1396出版社
ELSEVIER SCIENCE INC
DOI: 10.1097/JTO.0b013e3181b6b84b
关键词
Canfosfamide; Carboplatin; Paclitaxel; NSCLC; Phase 2
资金
- Telik, Inc.
- Palo Alto, CA.
Introduction: We aimed to evaluate the safety and efficacy of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer. Methods: This was a phase 1-2a, multicenter, dose-ranging trial that enrolled patients with stage IIIB or IV non-small cell lung cancer with measurable disease. Patients received canfosfamide in doses ranging from 400 to 1000 mg/m(2) intravenously (IV) with carboplatin at area under the curve 6 IV and paclitaxel at 200 mg/m(2) IV day I every 3 weeks. The primary end point was objective response rate, and the secondary endpoints were safety and progression-free survival. Results: One hundred twenty-nine patients were treated with canfosfamide at dose levels of 400 (n = 3), 500 (n = 51), 750 (n = 54), and 1000 mg/m(2) (n = 21). Objective tumor responses by RECIST were observed in 40 patients [34% (95% confidence interval [CI], 26-44)], the median progression-free survival was 4.3 months (95% Cl, 3.7-5.2) and the median survival 9.9 months (95% Cl, 7.7-11.9). The percent of patients alive at I year was 43.1%. The overall safety profile of the combination was acceptable and consistent with the profiles of the individual agents. In an exploratory analysis, patients receiving the optional maintenance canfosfamide therapy had a prolonged median Survival of 16.8 months compared with those eligible for but not receiving maintenance therapy at 8.8 months (hazard ratio = 0.38, p < 0.001). Conclusions: The combination of canfosfamide with carboplatin and paclitaxel chemotherapy is well tolerated and active. Maintenance canfosfamide may further improve outcomes. This regimen is worthy of additional study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据